Antibody-based therapeutics are prone to quality issues, including aggregation, byproducts, and post-translational modifications, that can negatively affect manufacturability, shelf life, and safety. The series provides direct detection of product aggregates, enabling a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process, the company said.

With Opto Assure, customers will be able to rapidly select clonal cell lines with favorable manufacturability profiles, ultimately reducing scale-up costs and improving downstream products, Berkeley Lights noted.

Berkeley Lights launches Opto Plasma B Discovery 4.0 workflow
Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.

Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with...

Optofluidics aids cell line development for antibody-based therapies
Implementation of optofluidics in cell line development can help advance multiple lead candidate molecules with increased screening capacity. A researcher...